Aggregated News
(Reuters) - Silicon Valley-based genetic testing company 23andMe is looking for new growth of its direct-to-consumer DNA tests abroad, building on recent expansions into Canada and the UK.
The company, whose consumer-directed tests were barred by U.S. health regulators in 2013, said Western Europe is one focus for expansion. It is also exploring regions where it sees the most need, 23andMe Co-founder and Chief Executive Anne Wojcicki said in an interview.
The U.S. Food and Drug Administration has said it fears the genetic information and analysis provided by 23andMe could be misinterpreted by customers. More than 800,000 people have taken the test globally. Neither Canada or the UK required premarket approval for distributing its tests, the company said.
23andMe's international expansion is part of a plan to reach an "unprecedented" number of consumers. Since the FDA decision, the company has continued to sell genealogy information to U.S. consumers and has also reached several sequencing deals with research institutions and drugmakers, which will use the data in a controlled environment.
"I want billions (of consumers)," Wojcicki said. "We would never have...